{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T04:44:00Z","timestamp":1778906640270,"version":"3.51.4"},"reference-count":30,"publisher":"Japanese Society of Internal Medicine","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2023,6,15]]},"DOI":"10.2169\/internalmedicine.0860-22","type":"journal-article","created":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T22:18:49Z","timestamp":1666736329000},"page":"1775-1779","source":"Crossref","is-referenced-by-count":4,"title":["Development of Fulminant Type 1 Diabetes Mellitus in the Course of Treatment with Atezolizumab for Hepatocellular Carcinoma"],"prefix":"10.2169","volume":"62","author":[{"given":"Munehiro","family":"Ikeda","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Takatsuki Red Cross Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Tamada","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Takatsuki Red Cross Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Risa","family":"Takebayashi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Takatsuki Red Cross Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaku","family":"Okuno","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Takatsuki Red Cross Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iori","family":"Yagura","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Takatsuki Red Cross Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shohei","family":"Nakamori","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Takatsuki Red Cross Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taishiro","family":"Matsumura","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Takatsuki Red Cross Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuto","family":"Yoshioka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Takatsuki Red Cross Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shizuka","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Department of Diabetes\/Endocrinology\/Metabolism, Takatsuki Red Cross Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Kanda","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Takatsuki Red Cross Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372: 2521-2532, 2015.","DOI":"10.1056\/NEJMoa1503093"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 382: 1894-1905, 2020.","DOI":"10.1056\/NEJMoa1915745"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol 4: 173-182, 2018.","DOI":"10.1001\/jamaoncol.2017.3064"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Gonz\u00e1lez-Rodr\u00edguez E, Rodr\u00edguez-Abreu D; Spanish Group for Cancer Immuno-Biotherapy (GETICA). Immune checkpoint inhibitors: review and management of endocrine adverse events. Oncologist 21: 804-816, 2016.","DOI":"10.1634\/theoncologist.2015-0509"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Guleria I, Gubbels Bupp M, Dada S, et al. Mechanisms of PDL1-mediated regulation of autoimmune diabetes. Clin Immunol 125: 16-25, 2007.","DOI":"10.1016\/j.clim.2007.05.013"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Gajewski TF. Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin Cancer Res 13: 5256-5261, 2007.","DOI":"10.1158\/1078-0432.CCR-07-0892"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. McDermott DF, Sosman JA, Sznol M, et al. Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study. J Clin Oncol 34: 833-842, 2016.","DOI":"10.1200\/JCO.2015.63.7421"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Hickmott L, De La Pe\u00f1a H, Turner H, et al. Anti-PD-L1 atezolizumab-induced autoimmune diabetes: a case report and review of the literature. Target Oncol 12: 235-241, 2017.","DOI":"10.1007\/s11523-017-0480-y"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Morran MP, Vonberg A, Khadra A, Pietropaolo M. Immunogenetics of type 1 diabetes mellitus. Mol Aspects Med 42: 42-60, 2015.","DOI":"10.1016\/j.mam.2014.12.004"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. van Belle TL, Coppieters KT, von Herrath MG. Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol Rev 91: 79-118, 2011.","DOI":"10.1152\/physrev.00003.2010"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Todd JA. Etiology of type 1 diabetes. Immunity 32: 457-467, 2010.","DOI":"10.1016\/j.immuni.2010.04.001"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Conrad B, Trucco M. Superantigens as etiopathogenetic factors in the development of insulin-dependent diabetes mellitus. Diabetes Metab Rev 10: 309-338, 1994.","DOI":"10.1002\/dmr.5610100402"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13. Roep BO. The role of T-cells in the pathogenesis of type 1 diabetes: from cause to cure. Diabetologia 46: 305-321, 2003.","DOI":"10.1007\/s00125-003-1089-5"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Mallone R, Martinuzzi E, Blancou P, et al. CD8+ T-cell responses identify beta-cell autoimmunity in human type 1 diabetes. Diabetes 56: 613-621, 2007.","DOI":"10.2337\/db06-1419"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Ansari MJI, Salama AD, Chitnis T, et al. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 198: 63-69, 2003.","DOI":"10.1084\/jem.20022125"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Wang J, Yoshida T, Nakaki F, Hiai H, Okazaki T, Honjo T. Establishment of NOD-Pdcd1<sup>-\/-<\/sup> mice as an efficient animal model of type I diabetes. Proc Natl Acad Sci U S A 102: 11823-11828, 2005.","DOI":"10.1073\/pnas.0505497102"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Steck AK, Rewers MJ. Genetics of type 1 diabetes. Clin Chem 57: 176-185, 2011.","DOI":"10.1373\/clinchem.2010.148221"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Noble JA, Erlich HA. Genetics of type 1 diabetes. Cold Spring Harb Perspect Med 2: a007732, 2012.","DOI":"10.1101\/cshperspect.a007732"},{"key":"19","doi-asserted-by":"publisher","unstructured":"19. Tisch R, McDevitt H. Insulin-dependent diabetes mellitus. Cell 85: 291-297, 1996.","DOI":"10.1016\/S0092-8674(00)81106-X"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Noble JA, Valdes AM. Genetics of the HLA region in the prediction of type 1 diabetes. Curr Diab Rep 11: 533-542, 2011.","DOI":"10.1007\/s11892-011-0223-x"},{"key":"21","doi-asserted-by":"publisher","unstructured":"21. Bluestone JA, Anderson M, Herold KC, et al. Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors. Diabetes 67: 1471-1480, 2018.","DOI":"10.2337\/dbi18-0002"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Baden MY, Imagawa A, Abiru N, et al. Characteristics and clinical course of type 1 diabetes mellitus related to anti-programmed cell death-1 therapy. Diabetol Int 10: 58-66, 2019.","DOI":"10.1007\/s13340-018-0362-2"},{"key":"23","doi-asserted-by":"crossref","first-page":"e59125","DOI":"10.1172\/jci.insight.59125","volume":"3","author":"A Osa","year":"2018","unstructured":"23. Osa A, Uenami T, Koyama S, et al. Clinical implications of monitorinig nivolumab immunokinetics in non-small cell lung cancer patients. JCI Insight 3: e59125, 2018.","journal-title":"JCI Insight","ISSN":"https:\/\/id.crossref.org\/issn\/2379-3708","issn-type":"print"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Hatayama S, Kodama S, Kawana Y, et al. Two cases with fulminant type 1 diabetes that developed long after cessation of immune checkpoint inhibitor treatment. J Diabetes Investig 13: 1458-1460, 2022.","DOI":"10.1111\/jdi.13807"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Nishioki T, Kato M, Kataoka S, Miura K, Nagaoka T, Takahashi K. Atezolizumab-induced fulminant type 1 diabetes mellitus occurring four months after treatment cessation. Respirol Case Rep 8: e00685, 2020.","DOI":"10.1002\/rcr2.685"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Yaura K, Sakurai K, Niitsuma S, Sato R, Takahashi K, Arihara Z. Fulminant type 1 diabetes mellitus developed about half a year after discontinuation of immune checkpoint inhibitor combination therapy with nivolumab and ipilimumab: a case report. Tohoku J Exp Med 254: 253-256, 2021.","DOI":"10.1620\/tjem.254.253"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Imagawa A, Hanafusa T, Awata T, et al. Report of the Committee of the Japan Diabetes Society on the research of fulminant and acute-onset type 1 diabetes mellitus: new diagnostic criteria of fulminant type 1 diabetes mellitus. J Diabetes Investig 3: 536-539, 2012.","DOI":"10.1111\/jdi.12024"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Zhang R, Cai XL, Liu L, Han XY, Ji LN. Type 1 diabetes induced by immune checkpoint inhibitors. Chin Med J (Engl) 133: 2595-2598, 2020.","DOI":"10.1097\/CM9.0000000000000972"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Gonz\u00e1lez-Rodr\u00edguez E, Rodr\u00edguez-Abreu D. Immune checkpoint inhibitors: review and management of endocrine adverse events. Oncologist 21: 804-816, 2016.","DOI":"10.1634\/theoncologist.2015-0509"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Zornitzki T, Malnick S, Lysyy L, Knobler H. Interferon therapy in hepatitis C leading to chronic type 1 diabetes. World J Gastroenterol 21: 233-239, 2015.","DOI":"10.3748\/wjg.v21.i1.233"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/12\/62_0860-22\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,17]],"date-time":"2023-06-17T03:27:39Z","timestamp":1686972459000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/12\/62_0860-22\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,15]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.0860-22","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,15]]},"article-number":"0860-22"}}